Vigil Neuroscience Stock Performance
| VIGL Stock | USD 2.25 0.02 0.88% |
The entity has a beta of 0.54, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Vigil Neuroscience's returns are expected to increase less than the market. However, during the bear market, the loss of holding Vigil Neuroscience is expected to be smaller as well. At this point, Vigil Neuroscience has a negative expected return of -0.65%. Please make sure to validate Vigil Neuroscience's standard deviation, treynor ratio, as well as the relationship between the Treynor Ratio and rate of daily change , to decide if Vigil Neuroscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vigil Neuroscience has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's technical and fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Actual Historical Performance (%)
One Day Return (0.88) | Five Day Return (8.16) | Year To Date Return (35.16) | Ten Year Return (82.21) | All Time Return (82.21) |
1 | Vigil stock gains as FDA removes partial hold | 09/17/2024 |
2 | Acquisition by David Gray of 267000 shares of Vigil Neuroscience at 12.09 subject to Rule 16b-3 | 09/19/2024 |
3 | Vigil Neuroscience shares maintain Outperform rating on positive FDA update - Investing.com | 09/20/2024 |
4 | We Think Vigil Neuroscience Needs To Drive Business Growth Carefully | 10/17/2024 |
5 | Disposition of 135000 shares by Ziolkowski Jennifer Lynn of Vigil Neuroscience at 11.87 subject to Rule 16b-3 | 10/31/2024 |
6 | Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update | 11/07/2024 |
7 | Vigil Neuroscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com | 11/14/2024 |
8 | Vigil Neuroscience Down On A Competitors Failure - Seeking Alpha | 12/02/2024 |
9 | Acquisition by Magovcevic-liebisch Ivana of 5000 shares of Vigil Neuroscience at 2.34 subject to Rule 16b-3 | 12/05/2024 |
10 | Vigil Neuroscience initiated with an Outperform at William Blair - MSN | 12/09/2024 |
| Begin Period Cash Flow | 186.6 M |
Vigil |
Vigil Neuroscience Relative Risk vs. Return Landscape
If you would invest 368.00 in Vigil Neuroscience on September 12, 2024 and sell it today you would lose (143.00) from holding Vigil Neuroscience or give up 38.86% of portfolio value over 90 days. Vigil Neuroscience is currently does not generate positive expected returns and assumes 4.8041% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Vigil, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vigil Neuroscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vigil Neuroscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vigil Neuroscience, and traders can use it to determine the average amount a Vigil Neuroscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1358
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VIGL |
Estimated Market Risk
| 4.8 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.65 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Vigil Neuroscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vigil Neuroscience by adding Vigil Neuroscience to a well-diversified portfolio.
Vigil Neuroscience Fundamentals Growth
Vigil Stock prices reflect investors' perceptions of the future prospects and financial health of Vigil Neuroscience, and Vigil Neuroscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vigil Stock performance.
| Return On Equity | -0.7 | ||||
| Return On Asset | -0.4 | ||||
| Current Valuation | (5.3 M) | ||||
| Shares Outstanding | 40.88 M | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (88.47 M) | ||||
| Net Income | (82.64 M) | ||||
| Cash And Equivalents | 148.91 M | ||||
| Cash Per Share | 5.27 X | ||||
| Total Debt | 13.85 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 21.35 X | ||||
| Book Value Per Share | 3.24 X | ||||
| Cash Flow From Operations | (70.36 M) | ||||
| Earnings Per Share | (2.07) X | ||||
| Market Capitalization | 92.8 M | ||||
| Total Asset | 140.86 M | ||||
| Retained Earnings | (222.77 M) | ||||
| Working Capital | 110.25 M | ||||
About Vigil Neuroscience Performance
By examining Vigil Neuroscience's fundamental ratios, stakeholders can obtain critical insights into Vigil Neuroscience's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Vigil Neuroscience is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.4 K | 3.1 K | |
| Return On Tangible Assets | (0.59) | (0.62) | |
| Return On Capital Employed | (0.69) | (0.72) | |
| Return On Assets | (0.59) | (0.62) | |
| Return On Equity | (0.71) | (0.68) |
Things to note about Vigil Neuroscience performance evaluation
Checking the ongoing alerts about Vigil Neuroscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vigil Neuroscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vigil Neuroscience generated a negative expected return over the last 90 days | |
| Vigil Neuroscience has high historical volatility and very poor performance | |
| Vigil Neuroscience has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (82.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Vigil Neuroscience currently holds about 148.91 M in cash with (70.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.27, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 80.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from news.google.com: Vigil Neuroscience initiated with an Outperform at William Blair - MSN |
- Analyzing Vigil Neuroscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vigil Neuroscience's stock is overvalued or undervalued compared to its peers.
- Examining Vigil Neuroscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vigil Neuroscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vigil Neuroscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vigil Neuroscience's stock. These opinions can provide insight into Vigil Neuroscience's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vigil Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Vigil Stock please use our How to buy in Vigil Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vigil Neuroscience. If investors know Vigil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vigil Neuroscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.07) | Return On Assets (0.40) | Return On Equity (0.70) |
The market value of Vigil Neuroscience is measured differently than its book value, which is the value of Vigil that is recorded on the company's balance sheet. Investors also form their own opinion of Vigil Neuroscience's value that differs from its market value or its book value, called intrinsic value, which is Vigil Neuroscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vigil Neuroscience's market value can be influenced by many factors that don't directly affect Vigil Neuroscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vigil Neuroscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vigil Neuroscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vigil Neuroscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.